Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________________________________________________________________ ______________________FORM 10-K (Mark One) ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39634 ______________________________________________________________________________________________ ...

Peter Kelleher, LifeSci Advisors (Investors) pkelleher@lifesciadvisors.com • Selective CBP and EP300 degrader preclinical data to be presented at AACR; IND-enabling studies for CBP degrader program planned to begin by end of 2024 • Foghorn anticipates at least six new INDs targeting significant oncology patient populations over the next four years, reflecting the continued productivity of its precision medicine platform • Cash, cash equivalents, and marketable securities of $234.1 million, as of December 31 ...

Poster presentation of FHD-909, a first-in-class oral BRM selective inhibitor, highlighting preclinical efficacy and safety in multiple mouse models of NSCLC; IND filing planned in Q2 2024 Oral presentation demonstrating preclinical efficacy and tolerability data for Selective CBP and Selective EP300 degraders; Significant anti-tumor activity observed, with no thrombocytopenia as historically observed with dual CBP/EP300 inhibitors Additional poster presentation demonstrating long-acting degrader capabiliti ...

Poster presentation of FHD-909, a first-in-class oral BRM selective inhibitor, highlighting preclinical efficacy and safety in multiple mouse models of NSCLC; IND filing planned in Q2 2024 Oral presentation demonstrating preclinical efficacy and tolerability data for Selective CBP and Selective EP300 degraders; Significant anti-tumor activity observed, with no thrombocytopenia as historically observed with dual CBP/EP300 inhibitors Additional poster presentation demonstrating long-acting degrader capabiliti ...

CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that it will participate in Cowen's 44th Annual Health Care Conference, which is taking place on March 4–6, 2024, at the Boston Marriott Copley Place in Boston, MA. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broa ...

Foghorn Therapeutics Inc. (FHTX) shares ended the last trading session 22.7% higher at $5.95. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 11.3% loss over the past four weeks.The sudden gain in the stock price can be attributed to the positive investor mindset regarding the company's pipeline. Last week, Foghorn announced that its pre-clinical candidate, FHD-909, has been selected by Eli Lilly for clinical devel ...

FoghornTherapeutics Inc. (FHTX) , a clinical-stage company, announced that its pre-clinical candidate, FHD-909, has been selected by Eli Lilly (LLY) for clinical development under the December 2021 strategic collaboration agreement to create novel oncology medicines.Per the terms of the December 2021 agreement, Foghorn and Lilly are co-developing and co-commercializing LLY’s Selective BRM oncology program and an additional undisclosed oncology target. Both companies are sharing the costs of development equa ...

CAMBRIDGE, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that Lilly has selected FHD-909, a first-in-class oral BRM selective inhibitor, for clinical development. Lilly plans to file an IND for FHD-909 in Q2 2024. The primary target patient population is BRG1 mutated non-small cell lung cancer (NSCLC). Selective BR ...

For the three and nine months ended September 30, 2023 and 2022, there were no transfers between Level 1, Level 2 and Level 3. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ______________________ _____________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR For the transition period from __________________ to __________________ Foghorn Therapeutics Inc. (Exact Name of Registrant as Specified in its Charter) _____________ ...

Table of Contents For the quarterly period ended June 30, 2023 Commission File Number: 001-39634 ______________________ 02139 (Zip Code) Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x As of July 31, 2023, the registrant had 41,862,174 shares of common stock, $0.0001 par value per share, outstanding. i • the initiation, timing, progress and results of our research and development programs, preclinical and clinical studies; 1 | --- | ...